Drug Trial Radar · NCT02441283
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Last checked: Nov 20, 2026Latest source record: Sep 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
384
Actual
Start
Jun 22, 2015
Primary completion
Oct 15, 2019
Study completion Oct 15, 2019
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.
Conditions
- Hepatitis C
Interventions
ABT-493Drug
ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
ABT-530Drug
ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Maintained a Sustained Virologic Response (SVR) Out of Those Who Achieved SVR12 in a Prior Study With an ABT-493- and/or ABT-530-containing RegimenTime frame: From the end of treatment in the previous study up to 3 years post-treatment
- Percentage of Participants Who Relapsed or Had a New Hepatitis C Virus (HCV) Infection at Any Time up to the Last Follow-up in This Study Among Participants Who Achieved SVR12 in a Prior Study With an ABT-493- and/or ABT-530-containing RegimenTime frame: From the end of treatment in the previous study up to 3 years post-treatment
- Number of Participants With Persistence of Resistance-Associated Amino Acid Variants Among Those Experiencing Virologic FailureTime frame: From Day 1 to Month 12
Locations
42 sites in 8 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast /ID# 136725
Dothan, Alabama
Felizarta /ID# 141033
Bakersfield, California
Southern California Res. Ctr. /ID# 141799
Coronado, California
Research & Education, Inc. /ID# 169591
San Diego, California
eStudySite San Diego /ID# 141040
San Diego, California
eStudySite San Diego /ID# 141047
San Diego, California
eStudySite San Diego /ID# 141048
San Diego, California
Midway Immunology and Research /ID# 169477
Ft. Pierce, Florida
Delta Research Partners /ID# 141028
Bastrop, Louisiana
Louisiana Research Ctr. LLC /ID# 141024
Shreveport, Louisiana
Henry Ford Health System /ID# 141039
Detroit, Michigan
Binghamton Gastroenterology /ID# 141026
Binghamton, New York
Carolinas Center for Liver Dis /ID# 155390
Statesville, North Carolina
Northwest Gastroenterology Cli /ID# 141036
Portland, Oregon
Gastro One /ID# 169478
Germantown, Tennessee
Quality Medical Research, PLLC /ID# 141042
Nashville, Tennessee
TX Clinical Research Institute /ID# 141037
Arlington, Texas
Inquest Clinical Research /ID# 141045
Baytown, Texas
TX Liver Inst, Americ Res Corp /ID# 136727
San Antonio, Texas
Bon Secours St. Mary's Hospita /ID# 165106
Richmond, Virginia
St. Vincent's Hospital, Darlinghurst /ID# 155395
Darlinghurst, New South Wales, Australia
St. Vincents Hospital /ID# 155394
East Lismore, New South Wales, Australia
Westmead Hospital /ID# 155392
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital /ID# 155396
Herston, Queensland, Australia
Royal Adelaide Hospital /ID# 155391
Adelaide, South Australia, Australia
Royal Melbourne Hospital /ID# 155393
Parkville, Victoria, Australia
CHU St. Pierre /ID# 155399
Brussels, Belgium
UZ Leuven /ID# 155398
Leuven, Belgium
Cliniques Universitaires Saint Luc /ID# 155397
Woluwe-Saint-Lambert, Brussels Capital, Belgium
University of Calgary /ID# 155400
Calgary, Alberta, Canada
Toronto Liver Centre /ID# 155401
Toronto, Ontario, Canada
Mauss, Schmutz, Hegener, Athma /ID# 155402
Düsseldorf, Germany
Gastroenterologisch-Hepatologi /ID# 169820
Kiel, Germany
Universitätsklinikum Frankfurt /ID# 169817
Frankfurt am Main, Hesse, Germany
Auckland City Hospital /ID# 155403
Auckland, New Zealand
Gastro-Hepato & Geriatric Ctr /ID# 141060
Ponce, Puerto Rico
Klinical Investigations Group /ID# 141059
San Juan, Puerto Rico
Innovative Care P.S.C. /ID# 141061
San Juan, Puerto Rico
King's College Hospital NHS /ID# 155406
London, United Kingdom
St. Mary's Hospital /ID# 155404
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.